Published in Medical Letter on the CDC and FDA, February 17th, 2002
"The approval of generic dexedrine spansule represents the company's ninth approval this fiscal year and the second product in our generic portfolio for the treatment of attention deficit disorder," said Bruce L. Downey, Barr's chairman and CEO. "With the anticipated approval of our generic Adderall application, which is currently pending at the FDA, Barr will be a leading provider of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.